The limited pilot soft launch of the Sputnik V vaccine in India, which was initiated by Dr Reddy's Laboratories in Hyderabad on May 14, has now been successfully scaled up to cities including Bengaluru, Mumbai, Chennai, Visakhapatnam, Kolkata, Delhi, Baddi, Kolhapur and Miryalaguda. 

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

Dr Reddy's Laboratories has informed that being a limited pilot phase presently, registration on CoWIN is not open yet to members of the public. This will become open at the time of our commercial launch.

See Zee Business Live TV Streaming Below:

Once the pilot phase is completed, Dr Reddy's will announce the commercial launch of the Sputnik V. 

Meanwhile, Sputnik V has also tweeted that “#Sputnik V will soon offer a booster shot, adjusted to work against the Delta variant of coronavirus, first detected in India, to other vaccine manufacturers. We’ve always said that vaccine cocktails are the way of the future. We offer all vaccine makers to use our shot in cocktails against #COVID mutations.”

Dr Reddy's Laboratories is the brand custodian of the Sputnik vaccine in India and has the sole distribution rights of the first 250 million doses, including first and second dose components of the vaccine in India.  

Earlier, the commercial launch of the Sputnik V vaccine was expected in mid-June.

This pilot phase will allow Dr Reddy's to test its cold storage arrangement of -18 degree C temperature in these cities, CoWIN integration, track-and-track and other logistical arrangements ahead of our commercial launch. 

The limited pilot phase is currently in its final leg as Dr Reddy's gears up to ensure a smooth commercial launch.  

Adequate numbers of cold chain units are being deployed and the last mile cold chain arrangement is being validated at every partner hospital to ensure seamless storage and handling of the vaccine.  

All necessary supply arrangements are being executed to ensure availability of both dose components in the right quantity and at the right time at partner hospital, the pharma company informed.